#TherapeuticEfficacy Archives

Allogeneic Hematopoietic Stem Cell Transplantation: A Salvage Option for Diffuse Large B-Cell Lymphoma Patients After CAR-T Therapy Failure

By Yang Xiaoshan 2024.03.17

Abstract: Refractory/relapsed diffuse large B-cell lymphoma (R/R DLBCL) poses significant therapeutic challenges, particularly in cases where chimeric antigen receptor T-cell (CAR-T) therapy fails. This retrospective study aimed to evaluate the…

$Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results$

Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results

By Mourabit Halima 2024.03.17

Abstract: Multiple myeloma (MM) poses significant therapeutic challenges due to its heterogeneous nature. Bispecific chimeric antigen receptor T (CAR-T) cell therapy targeting CS1 and BCMA antigens offers a novel approach.…

Evaluating the Efficacy and Safety of Orelabrutinib-Based Regimens in Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

By Mourabit Halima 2024.03.17

Abstract: Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous malignancy associated with significant morbidity and mortality. Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown promise as a therapeutic agent…